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Abstract 
Background: The overall usefulness of palliative thoracic re-irradiation depends on 
the balance between efficacy, survival and toxicity, and is difficult to judge from 
previous studies. In the absence of patient-reported data, we developed a method 
for provider decision regret that addresses the question “would we re-irradiate this 
patient again in light of the known outcome?” Furthermore, we analyzed different 
reasons for decision regret and defined a subgroup at increased risk. 
Patients and Methods: A retrospective analysis of 33 patients with lung cancer re-
irradiated with 17-45 Gy was performed. Reasons for decision regret included re-
irradiation within the last 30 days of life, immediate radiological progression after 
re-irradiation (as opposed to stable disease or objective response), radiation 
myelopathy, any grade 4-5 toxicity, grade 3 pneumonitis, other grade 3 toxicity in 
the absence of a symptomatic benefit or a time period of at least 3 months without 
worsening of the treated tumor. 
Results: Median survival time was 5.2 months (95% confidence interval 3.4-7.0 
months). Symptomatic and radiological responses were observed. Provider 
decision regret was declared in 12 patients (36%, two patients with grade 3 
pneumonitis, three patients with a short survival (radiotherapy during the last 30 
days of life), seven patients with progression). Decision regret was declared only 
in patients with ECOG performance status (PS) 2 or 3 and was associated with 
time interval to re-irradiation <6 months.  
Conclusion: Our data support the usefulness and acceptable side effect profile of 
palliative re-irradiation for lung cancer. Patients with reduced PS are at increased 
   
risk of futile treatment. Future research should aim at prediction of immediate 
disease progression (the prevailing cause of decision regret). Evaluation of 
provider decision regret has the potential to improve the way we learn from 
retrospective databases and should also be considered for other scenarios where 
high-quality prospective outcome data are lacking.       
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Re-irradiation for symptom palliation has long been used in a large number of 
different clinical scenarios [1], including advanced lung cancer [2]. It has also been 
shown that selected patients with non-small cell lung cancer (NSCLC) are able to 
tolerate high-dose re-irradiation, which aims beyond relief of symptoms [3-5]. In 
contrast to other indications, no randomized trials of lung cancer re-irradiation have 
been published [6]. Evidence is derived mainly from few small single-arm 
prospective studies and a considerable number of retrospective analyses. Most of 
these reported limited data about the overall usefulness of palliative re-irradiation 
and did not fully answer the following questions. Did re-irradiation result in 
symptom relief or prolong the time without worsening of the thoracic tumor? Was 
survival long enough to justify re-irradiation as compared to simpler palliative and 
supportive interventions? Did re-irradiation cause high-grade toxicity? We were 
interested in analyzing the usefulness of re-irradiation based on a composite 
endpoint integrating all the aspects mentioned above, resembling the concept of 
uncomplicated cure in first-line settings. Furthermore, we asked the question “do 
we regret our decision to offer re-irradiation in light of the observed outcome or 
would we do it again?” In the absence of patient-reported data, this kind of 
provider-based retrospective decision regret analysis may shed additional light on 
the current controversies around palliative thoracic re-irradiation.        
    
Patients and Methods 
This is a retrospective single-institution study based on a previously described 
database that is maintained in order to analyze the quality of care for patients with 
   
lung cancer at our institution [7]. Staging information in the database relates to the 
TNM 7th edition and response data to RECIST 1.1. All patients re-irradiated for in-
field or marginal recurrence to overlapping thoracic target volumes between 2011 
and 2018 were identified from the database and included in the study. The 
following criteria for decision regret were applied: re-irradiation within the last 30 
days of life, immediate radiological progression after re-irradiation (as opposed to 
stable disease or objective response), radiation myelopathy, any grade 4-5 toxicity 
(CTC AE version 4.0), grade 3 pneumonitis, other grade 3 toxicity in the absence 
of a symptomatic benefit or a time period of at least 3 months without worsening 
of the treated tumor. We arbitrarily decided that grade 3 toxicities other than 
pneumonitis might be acceptable if “compensated” by a benefit from re-irradiation, 
but we acknowledge that patient-reported data and judgements would be 
preferable to confirm this perspective. Grade 2 pneumonitis was registered as well. 
Re-irradiation was offered on a case-by-case basis, irrespective of target volume 
size, time interval and previous dose, and without applying any standardized dose 
constraints, except for spinal cord where we used our previously published risk 
model to ensure the patients had a low or intermediate risk of myelopathy [8]. 
Patients with interstitial lung disease or grade ≥2 pneumonitis after initial 
radiotherapy were not re-irradiated. No lower limit was applied for any lung function 
parameter. A 3-D conformal technique was used and, when available, the initial 
treatment plan was co-registered to the re-irradiation plan. Motion management 
(4-D computed tomography (CT), deep inspiration breath hold) and positron 
emission tomography were not mandatory. Dose-fractionation regimens were 
   
individualized. Dose was prescribed to the reference point, and the clinical target 
volume received at least 95% of the prescribed dose, unless coverage was 
reduced to protect normal tissues. Variable minimum planning target volume 
coverage was accepted, however the 90% isodose was to enclose 98% of the 
volume whenever feasible. Follow-up took place every three months and included 
clinical examination and chest and abdomen CT. Symptoms were not quantified 
on any particular assessment scale. The electronic patient records (including 
physician and oncology nurse notes) and radiology reports were assessed to 
collect follow-up data. Date of death was also registered in these records. Survival 
was calculated from the first day of re-irradiation.  
 
Results 
Thirty-tree patients were analyzed (22 males; two largest histology groups: 19 with 
squamous cell, 6 with small cell (SCLC) tumors). Only 8 patients (24%) had 
received a curative regimen as their first treatment. Fifteen patients had received 
systemic treatment before re-irradiation (chemotherapy, targeted agents, immune 
checkpoint inhibitors). More than 10 different fractionation regimens were used in 
first line (median dose 39 Gy), e.g., 2 fractions of 8.5 Gy (day 1 and 8; 21%), 10 
fractions of 3 Gy (15%), and 15 fractions of 2.8 Gy (12%). Comparable 
heterogeneity was observed for re-irradiation (Table 1, median dose 30 Gy). In 6 
cases (18%), re-irradiation dose was higher than the previous dose. Common 
regimens included 2 fractions of 8.5 Gy (n=10, 30%) and 10 fractions of 3 Gy (n=7, 
21%). Eight patients (24%) received two courses with identical fractionation, e.g., 
   
10 fractions of 3 Gy or 2 fractions of 8.5 Gy. The median time interval from first to 
second radiotherapy was 10 months (minimum 3 months, maximum 61 months). 
Eight patients (24%) were re-irradiated after less than 6 months and 6 (18%) after 
more than 2 years. All patients completed their prescribed course of re-irradiation.               
The median age at re-irradiation was 70 years (range 47-86) and 12 patients (40%) 
were 75 or older. Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) was 0-1 in 7 patients (21%), 2 in 15 patients (45%), and 3 in the 
remaining 11 patients (33%). The reason for re-irradiation was superior vena cava 
compression (n=2), nodal relapse at the margin of the previous target volume 
(n=1), consolidation of chemotherapy response (n=1), thoracic pain (n=7), lung 
symptoms (dyspnea, cough, hemoptysis; n=9), and in-field imaging progression 
(n=13). Pain improved in 3 of 7 cases. Lung symptoms improved in 3 of 9 cases. 
Regarding the 14 patients with imaging progression/nodal relapse, 5 obtained 
partial remissions and 8 stable disease. Fifteen patients (45%) had documented 
imaging progression in the re-irradiated region before death, and this was often 
the cause of death. Eleven patients (33%) were not in contact with the hospital in 
the final phase before death, and therefore the cause of death was defined as 
unknown after review of the patient records.                 
The median overall survival time was 5.2 months (95% confidence interval 3.4-7.0 
months) and 4 patients (12%) were alive 1 year after the start of re-irradiation. 
Responders (imaging or symptoms) had better survival than patients with stable 
or progressive disease as their best response (Figure 1). One patient developed 
grade 2 and two grade 3 pneumonitis (overall 9% ≥ grade 2). Radiation myelopathy 
   
or grade 4-5 toxicity was not observed. Grade 1-2 esophagitis, fatigue and 
asthenia were recorded in up to 30%.      
The retrospective chart review resulted in provider decision regret in 12 patients 
(36%). Two of these decisions were triggered by grade 3 pneumonitis, three from 
short survival (radiotherapy during the last 30 days of life; in one case combined 
with lack of efficacy), and seven from lack of efficacy. Decision regret was declared 
only in patients with ECOG PS 2 or 3. All 12 patients were scheduled to spend no 
more than 10 working days on re-irradiation. Shorter time interval showed a 
statistical trend towards decision regret (p=0.09 for <6 months vs. at least 6 
months). The rates were 63% (<6 months), 32% (6-24 months), and 17% (>24 
months). Gender, age, presence of SCLC and a diagnosis of stage IIIB or IV 
disease were not associated with decision regret (chi-square test p>0.1). Median 
overall survival in the decision regret subgroup was 2.0 months. Regarding all PS 
3 patients, median overall survival was 3.5 months (maximum 11.5 months).        
 
Discussion 
Despite increasing numbers of systemic treatment options and continuous 
improvement of local therapies, many patients with lung cancer relapse [9-11]. 
Palliative thoracic re-irradiation may contribute to symptom improvement and, in 
some cases, improved survival due to its ability to delay the process of tumor 
growth. These aims (symptom control, growth control) were also the most common 
reasons for referral in the present study. However, less than 50% of the patients 
had documented improvement of lung symptoms, pain and tumor size on CT 
   
imaging. Retrospective chart review is not the best method to evaluate symptom 
improvement and quality of life. Patient-reported outcome data and decision regret 
analyses provide a better picture of the usefulness of treatment. However, such 
information is not available in the literature of palliative thoracic re-irradiation. The 
fact that responders had better survival than non-responders (Figure 1) supports 
the potential role of re-irradiation. Ideally, patients unlikely to respond would be 
spared the burden of treatment. Yet, internationally accepted models of response 
prediction are not available in this setting. Decision-making also has to 
acknowledge the potential of serious toxicity from thoracic radiotherapy. 
 
In the absence of patient-reported data we were interested in exploring alternative 
ways to judge the usefulness of palliative thoracic re-irradiation. Since it is 
unknown if some of our patients did regret their decision to undergo treatment, we 
decided to create criteria for provider decision regret. Those included short survival 
(radiotherapy during the last 30 days of life, an endpoint also evaluated in different 
other recent studies [12, 13]), lack of efficacy (defined as immediate thoracic 
disease progression without a period of stable or shrinking disease), and serious 
toxicity (myelopathy, any grade 4-5, selected grade 3). Of course, other criteria 
could have been selected. However, the present ones may serve as a starting 
point from which future recommendations can be derived, if the radiation oncology 
community agrees that this type of chart review adds value to the way we learn 
from real-world databases. Based on the present decision regret criteria, we found 
that we would not offer re-irradiation again to 36% of the patients who actually 
   
received it. The main cause was lack of efficacy. Only 3 (9%) and 2 patients (6%) 
had received radiotherapy during the last 30 days of life, and developed serious 
toxicity (grade 3 pneumonitis), respectively. In general, overall survival and toxicity 
profile do not discourage palliative thoracic re-irradiation.  
 
We did not perform detailed analyses of cumulative doses and correlations of 
outcome and dosimetric data in this relatively small cohort with heterogeneous 
treatment approaches, due to limited statistical power and lack of ability to validate 
our findings. However, it appears that regimens such as 17 Gy in 2 fractions and 
30-39 Gy in 10-13 fractions are feasible, even in our population of mostly elderly 
patients with compromised ECOG PS. Both, patients with SCLC and NSCLC were 
among those who derived benefit from re-irradiation. If needed to reduce the 
biologically effective dose to organs at risk, two daily fractions of 1.5-2 Gy can be 
prescribed. Eventually, fractionation should be chosen taking into account aim 
(symptom relief or tumor cell kill), survival prognosis, and tolerance of critical 
structures.                
 
As shown in Tables 2-4 the previous studies reported quite heterogeneous 
outcomes after re-irradiation to median doses that often were in the range of 30-
40 Gy. However, toxicity rates were acceptable and responses were observed in 
all studies, though survival beyond 12 months was relatively unlikely. Kramer et al. 
[17] confirmed this observation, using 2 fractions of 8 Gy given with one week split. 
The median overall survival was 5.6 months and 71% of patients had partial or 
   
complete relief of one or more of their symptoms. Relief of dyspnea, hemoptysis, 
and cough was observed in 35%, 100%, and 67%, respectively. Karnofsky 
performance status (KPS) improved in 45% patients. The overall median duration 
of symptom relief was 4 months. Poltinnikov et al. [23] were the first to report on 
the use of hypofractionated stereotactic re-irradiation (SBRT) in patients previously 
treated with concurrent chemoradiotherapy. The median dose of the 
hypofractionated schedule was 32 Gy (range, 4-42 Gy), with a median fraction size 
of 4 Gy (range, 2.5-4.2 Gy) delivered 3-5 times per week. Five patients also 
received concurrent chemotherapy. Radiologic response was observed in 5 (29%), 
and stable disease in another 5 (29%) patients. The median survival from the start 
of re-irradiation was 5.5 months. Symptom resolution was observed in 85% of 
symptomatic patients. No grade 3 or higher side effects were observed. Survival 
outcomes were better in the study by Patel et al. [24]. Previous median radiation 
dose was 61.2 Gy with a median 8-month interval from previous radiation. The 
median re-irradiation dose was 30 Gy (SBRT, n=26). Two-year actuarial local 
control was 65% (survival 37%). Fifty-five percent of patients reported 
acute/chronic grade 1 and 2 toxicities. No grade 3 or higher toxicities were 
reported. High-dose SBRT will not be discussed in detail because our study has 
focused on palliative regimens. Since brachytherapy is limited to patients with 
accessible, endoluminal disease this approach will not be discussed either.  
 
Few studies have provided data on predictive factors for radiation pneumonitis 
after palliative re-irradiation. Due to the low number of events, we refrained from 
   
further evaluation. Recently, Ren et al. analyzed 67 patients, 18 of whom with 
grade 3-4 pneumonitis [25]. Multivariate analysis revealed that mean lung dose 
(MLD) of the initial plan, V5 of the composite plans, and overlap-V5/re-V5 were 
independent predictors for grade ≥ 3 pneumonitis. However, independently 
validated models are lacking. Most previous studies date back to the pre-
immunotherapy era. Even if our experience is limited to two patients (nr. 13 and 
14, Table 1) who received PD1 inhibitors between first and second radiotherapy, 
toxicity problems such as pneumonitis were not encountered.    
 
Despite inherent limitations of small retrospective studies our data showed that 
even patients with ECOG PS3 did not have a uniformly poor prognosis. 
Nevertheless, decision regret was only declared in patients with PS2-3, meaning 
that PS is an important factor to consider during decision-making. Time interval <6 
months also played a role. In contrast, age and stage were not of high relevance. 
The fact that patients with retrospective provider decision regret were scheduled 
to spend no more than 10 working days on re-irradiation suggests that the 
prescribing physician was aware of the serious prognosis and potential for futile 
treatment. However, the underlying clinical information was probably too complex 
to be reflected in the limited data extracted for this study. A previous study 
performed in the first-line palliative irradiation setting revealed that PS, serum 
lactate dehydrogenase, C-reactive protein, liver/adrenal gland metastases, and 
extrathoracic disease status significantly predicted survival [7]. The poor prognosis 
patients survived for a median of 0.8 months. It would be interesting to analyze 
   
whether or not blood biomarkers or other parameters, e.g., imaging features, also 
could be helpful in predicting futile re-irradiation. In conclusion, this study supports 
the usefulness and acceptable side effect profile of palliative re-irradiation for lung 
cancer and encourages research towards prediction of immediate disease 
progression (the prevailing cause of decision regret).    
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Table 1. Patient data  
 
Number Baseline information (1. 
radiotherapy) 
First regimen, response Second regimen, previous 
treatment 
Clinical information (2. 
radiotherapy), indication 
Results Decision regret 
(reason) 
1 Male, ASCC T4 left lung, 
relapse after surgery and 
CTx, stage IIIB  
July 2013, 13 fr of 3 Gy, 
partial response 
December 2013, 10 fr of 3 
Gy, none 
68 yr, PS 2                
pain 
OS 7.7 mo     
pain improved 
death from met 
No 
2 Male, SCC T2 left lung, 
stage IIIA and brain met 
January 2012, 10 fr of 3 
Gy, partial response 
October 2013, 17 fr of 2.5 
Gy, CTx 
73 yr, PS 1        
radiological progress 




3 Male, LC mediastinal 
nodes, relapse after 
surgery and CTx, stage IIIA  
July 2011, 15 fr of 2.8 Gy, 
partial response 
April 2012, 15 fr of 2 Gy 
and 3 fr of 2.5 Gy, none 
58 yr, PS 1                
pain 
OS 7.6 mo      




4 Female, no histology, left 
lung, new lesion after SBRT 
May 2012, 10 fr of 3 Gy, 
stable disease 
October 2012, 10 fr of 3 
Gy, none 
70 yr, PS 3                  
pain 
OS 9.5 mo      
pain improved   
death from prog 
No 
5 Male, SCC T4 right lung, 
stage IIIB 
December 2012, 10 fr of 3 
Gy, stable disease 
July 2013, 10 fr of 3 Gy, 
none 
73 yr, PS 2, liver met                    
v. cava compression 
OS 3 mo         
stable disease    
death from met 
No 
6 Female, SCC T4 left lung, 
stage IIIB 
December 2013, 2 fr of 
8.5 Gy, stable disease 
September 2014, 10 fr of 3 
Gy, none 
77 yr, PS 2                
lung symptoms 
OS 6.4 mo    
symptoms 
No 
   
improved     
unknown cod 
7 Male, SCC T3 right lung, 
stage IIIB, primary CTx 
May 2014, 15 fr of 2.8 Gy 
and 5 fr of 2.6 Gy, partial 
response 
December 2016, 20 fr of 
1.75 Gy BID, CTx* 
79 yr, PS 1     
radiological progress 
OS 7.4 mo   
partial response  
death from prog 
No 
8 Female, SCC T2 left lung, 
stage I 
December 2012, 35 fr of 2 
Gy, partial response 
January 2015, 13 fr of 3 
Gy, none 
68 yr, PS 3     
radiological progress 
OS 11.5 mo  
stable disease   
unknown cod 
No 
9 Female, SCC T3 left lung, 
stage IIIA  
March 2015, 15 fr of 3 Gy, 
partial response 
April 2016, 2 fr of 8.5 Gy, 
none 
85 yr, PS 3                
lung symptoms 
OS 10.7 mo       
symptoms 
improved     
death from prog 
No 
10 Male, SCC T2 left lung, 
stage I, local and nodal 
progress after SBRT 
March 2013, 3 fr of 20 Gy, 
partial response 
April 2015, 15 fr of 2.8 Gy, 
CTx* 
70 yr, PS 1     
radiological progress 
OS 36 mo 
(ongoing)        
relapse free 
No 
11 Male, SCC T3 right lung, 
stage IV, primary CTx  
June 2015, 2 fr of 8.5 Gy, 
stable disease 
February 2016, 8 fr of 4 
Gy, CTx* 
64 yr, PS 2     
radiological progress 
OS 17.5 mo   
stable disease    
death from prog 
No 
12 Male, no histology, T4 left 
lung, pleural met 
April 2016, 2 fr of 8.5 Gy, 
stable disease 
July 2016, 2 fr of 8.5 Gy, 
none 
86 yr, PS 2                
pain 
OS 4.4 mo           
not improved      
unknown cod 
No 
   
13 Male, no histology, T4 right 
lung, stage IIIB 
February 2016, 13 fr of 3 
Gy*, stable disease 
January 2017, 5 fr of 5.5 
Gy, PD1 inhibitor 
47 yr, PS 3                
lung symptoms 
OS 6.7 mo         
not improved        
unknown cod 
No 
14 Male, SCC T2 right lung, 
stage IIIA 
August 2016, 15 fr of 2.8 
Gy*, stable disease 
August 2017, 26 fr of 1.5 
Gy BID, PD1 inhibitor 
67 yr, PS 3                  
lung symptoms 
OS 3.5 mo      
improved           





15 Male, SCC T3 left lung, 
stage IV, primary CTx 
September 2017, 2 fr of 
8.5 Gy, partial response 
April 2018, 2 fr of 8.5 Gy, 
CTx* 
68 yr, PS 2            
radiological progress 
OS 4.0 mo      
partial response    
death from prog 
No 
16 Male, SCC T4 right lung, 
stage IIIB 
July 2016, 10 fr of 3.75 
Gy, partial response 
December 2016, 2 fr of 8.5 
Gy, none 
81 yr, PS 3                  
pain 
OS 2.0 mo          
not improved     
death from prog 
Yes (Prog) 
17 Female, SCC T4 left lung, 
stage IIIB, induction CTx 
and converted from radical 
to palliative RT 
December 2014, 1 fr of 2 
Gy and 2 fr of 8.5 Gy, 
stable disease  
April 2015, 2 fractions of 
8.5 Gy, none 
74 yr, PS 3      
radiological progress 
OS 5.6 mo     
local progress   
unknown cod 
Yes (Prog) 
18 Male, adeno T4 right lung, 
stage IV, primary CTx 
June 2015, 2 fr of 8.5 Gy, 
stable disease 
October 2015, 2 fr of 8.5 
Gy, CTx* 
57 yr, PS 2                
pain 
OS 1.9 mo            
not improved       
death from prog 
Yes (Prog) 
   
19 Male, no histology, left lung, 
local progress after SBRT 
July 2012, 3 fr of 20 Gy, 
partial response 
September 2013, 10 fr of 3 
Gy, none 
66 yr, PS 2, adrenal met   
radiological progress 
OS 5.3 mo     
local progress    
unknown cod 
Yes (Prog) 
20 Female, SCC T3 left lung, 
stage IIIA 
April 2014, 35 fr of 2 Gy* 
partial response 
September 2015, 7 fr of 4 
Gy, CTx* 
56 yr, PS 2               
lung symptoms 
OS 3.0 mo      
not improved       
death from prog 
Yes (Prog) 
21 Male, adeno T2 right lung, 
stage IV, primary CTx 
September 2015, 2 fr of 
8.5 Gy, stable disease                      
May 2016, 2 fr of 8.5 Gy, 
none
70 yr, PS 3               
lung symptoms 
OS 1.7 mo             




22 Male, SCC left lung, stage 
IV, primary CTx 
November 2013, 10 fr of 3 
Gy, stable disease 
September 2014, 10 fr of 3 
Gy, none  
75 yr, PS 3                    
pain 
OS 1.6 mo       
not improved   
death from prog  
Yes (Prog) 
23 Female, SCC T3 right lung, 
stage IIIA, primary CTx 
July 2015, 2 fr of 8.5 Gy  
partial response 
October 2015, 2 fr of 8.5 
Gy, CTx* 
75 yr, PS 2     
radiological progress 
OS 5.2 mo    
stable disease      
gr 3 pneumonitis   
death from met 
Yes (Tox) 
24 Male, SCC T1 right lung, 
stage IV, CTx 
contraindication 
October 2015, 10 fr of 
4.25 Gy, partial response 
September 2016, 16 fr of 2 
Gy BID, none 
76 yr, PS 2               
lung symptoms 
OS 4.0 mo      
not improved          
gr 3 pneumonitis     
unknown cod 
Yes (Tox) 
   
25 Male, SCC T4 left lung, 
stage IIIB 
April 2016, 5 fr of 4 Gy, 
stable disease 
August 2016, 10 fr of 3 Gy, 
none 
63 yr, PS 2               
lung symptoms 
OS 1.3 mo        
not improved        
death from prog 
Yes (OS and 
Prog) 
26 Male, adeno T2 right lung, 
stage IIIA 
November 2014, 33 fr of 2 
Gy*, partial response 
January 2017, 2 fr of 8.5 
Gy, targeted therapy 
83 yr, PS 3               
lung symptoms 
OS 0.3 mo          
not improved        
death from prog 
Yes (OS) 
27 Male, SCC T4 right lung, 
stage IIIB  
April 2010, 15 fr of 2.8 Gy 
partial response 
January 2011, 2 fr of 8.5 
Gy, v. cava stent and CTx* 
63 yr, PS 3                   
v. cava compression  
OS 0.5 mo      
death from fall 
Yes (OS) 
28 Female, SCLC extensive 
disease, left lung 
June 2013, 10 fr of 3 Gy 
consolidation after CTx, 
stable disease 
November 2014, 15 fr of 3 
Gy, none 
59 yr, PS 0     
radiological progress  
OS 12.5 mo   
partial response   
adrenal met  
unknown cod 
No 
29 Male, SCLC limited 
disease, left lung  
September 2006, 15 fr of 
2.8 Gy*, partial response 
October 2011, 14 fr of 2.5 
Gy, CTx* 
52 yr, PS 1             
nodal relapse 
OS 7 mo      
stable disease   
death from met 
No 
30 Male, SCLC limited disease 
(yet malignant pleural 
effusion), right lung, CTx 
and sequential RT  
January 2015, 30 fr of 1.5 
Gy BID and 4 fr of 2 Gy, 
partial response 
March 2017, 9 fr of 3 Gy, 
CTx*  
73 yr, PS 2   
consolidation of CTx 
response 
OS 7 mo      
stable disease    
gr 2 pneumonitis 
after 2.5 mo CTx 
for local progress  
death from prog 
No 
   
31 Female, SCLC limited 
disease, right lung, CTx 
and sequential RT 
January 2016, 34 fr of 1.5 
Gy BID, complete 
response 
June 2017, 6 fr of 4 Gy, 
none 
79 yr, PS 2    
radiological progress 
OS 4.5 mo      
partial response    
unknown cod 
No 
32 Female, SCLC limited 
disease, right lung 
April 2016, 30 fr of 1.5 Gy 
BID*, partial response 
August 2017, 7 fr of 3.5 
Gy, CTx* 
77 yr, PS 1, lung met    
radiological progress 
OS 3.9 mo           
stable disease        
death from prog 
No 
33 Female, SCLC limited 
disease, right lung, CTX 
alone, later RT for 
mediastinal relapse 
October 2017, 5 fr of 4 
Gy, partial response 
June 2018, 5 fr of 5 Gy, 
none 
79 yr, PS 2               
radiological progress 
OS 1.7 mo       
stable disease          
liver met            
death from met 
No 
SCC: squamous cell cancer, ASCC: adenosquamous cell cancer, LC: large cell cancer, SCLC: small cell cancer 
CTx: systemic chemotherapy 
PS: Eastern Cooperative Oncology Group performance status 
OS: overall survival from first date of re-irradiation 
Met: distant metastases 
Cod: cause of death 
SBRT: stereotactic body radiotherapy 
Prog: thoracic disease progression 
Tox: radiation-induced toxicity 
BID: two fractions per day, minimum interval 6 hours 
*including concomitant platinum-based chemotherapy 
 
   
Figure 1. Actuarial overall survival (Kaplan-Meier curves) for 11 responders (imaging or symptoms) and 22 patients with 
stable or progressive disease (median 7.6 vs. 3.9 months, p=0.05, log-rank test). 
 
   
  
 
 
